权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Towards NanoMedicine Interventions for HIV/AIDS

针对艾滋病毒/艾滋病的纳米医学干预

基本信息

批准号：
EP/K002201/1
负责人：
Steven Rannard
金额：
$ 169.87万
依托单位：
University of Liverpool
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2012
资助国家：
英国
起止时间：
2012 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=EP%2FK002201%2F1
关键词：
Towards NanoMedicine Interventions HIV AIDS

项目摘要

Nanomedicines have proven extremely valuable in recent years and many are used daily to treat patients with a range of conditions or needs - from the treatment of cancer and menopausal symptoms to the prevention of organ rejection or malnutrition/weight loss. A range of unmet clinical needs may benefit considerably from the research and application of new nanoparticle synthesis techniques and the development of appropriate nanomedicines and provision of scale-able, commercially viable technologies that can impact patient outcomes is a key goal of nanomedicine research.Validation of new technologies through optimisation of product performance, demonstration of pharmaceutically relevant manufacturing and in-man pharmacokinetic studies is critical for progression as is the study of nanotoxicology to establish a safety assessment that supports future investment.To date, a series of candidate nanomedicines for HIV/AIDS treatment have been generated at the University of Liverpool in collaboration with IOTA NanoSolutions Ltd, a specialist start-up company in the UK, and supported by RCUK funding. IOTA is commercialising a novel nanoparticle synthesis technology (initially developed at UoL with EPSRC funding support) that rivals the most successful commercial top-down nanomedicine technology - nanomilling. The HIV/AIDS nanomedicine candidates have been the subject of 3 patent filings and funds are sought to optimise their production and establish their behaviour using clinical research techniques. Additionally the project will seek to dramatically increase the understanding of nanomedicine through fundamental mechanistic studies, thereby producing new insight into the mode of action and the safety of future nanomedicines.If successful, the programme will produce the first nanomedicine options for HIV/AIDS therapy with benefits for patient care potentially including lower dosing, reduced side effects, better patient-to-patient consistency and a reduction of tablet size. Significant interest has been generated within Medecins Sans Frontiere who are keen to utilise the outputs for charitable medicines in the developing world, treating children with HIV infection with better products and prevent HIV infection in newborns. Currently, to prevent transmission of HIV to children from infected mothers, the World Heath Organisation has recommended dosing from 3 weeks after birth with antiretrovirals. The only children's medicines available include high levels of alcohol to dissolve the poorly water-soluble drugs. The nanomedcines within this programme are dispersible in water and offer a step-forward in paediatric therapy. The successful establishment of the fundamental research underpinning new nanomedicines will provide a clear advance in the UK's global standing in this emerging area, currently valued at >US$75bn and growing rapidly, with expectations to reach >US$100bn within 3 years.

近年来，纳米医学已被证明是非常有价值的，许多纳米医学每天都被用于治疗患有一系列疾病或需求的患者-从治疗癌症和更年期症状到预防器官排斥或营养不良/体重减轻。一系列未得到满足的临床需求可能会从新的纳米颗粒合成技术的研究和应用中受益匪浅，适当的纳米医学的开发和提供可影响患者结局的可扩展的商业可行技术是纳米医学研究的关键目标。制药相关的生产和人体药代动力学研究的证明对于进展至关重要，因为纳米毒理学研究建立了支持未来投资的安全性评估。利物浦大学与英国一家专业初创公司IOTA NanoSolutions Ltd合作，在RCUK基金的支持下，开发了一系列用于艾滋病毒/艾滋病治疗的候选纳米药物。IOTA正在商业化一种新的纳米颗粒合成技术（最初在UoL开发，由EPSRC资助），可与最成功的商业自上而下的纳米医学技术-纳米研磨相媲美。艾滋病毒/艾滋病纳米药物候选人已经成为3项专利申请的主题，并寻求资金来优化其生产并使用临床研究技术建立其行为。此外，该项目将寻求通过基本的机制研究大大提高对纳米医学的理解，从而对未来纳米医学的作用模式和安全性产生新的见解。如果成功，该项目将产生第一个用于艾滋病毒/艾滋病治疗的纳米医学选择，其对患者护理的好处可能包括更低的剂量，减少副作用，更好的患者间一致性和片剂尺寸的减小。无国界医生组织内部产生了很大的兴趣，他们热衷于将产出用于发展中国家的慈善药品，用更好的产品治疗感染艾滋病毒的儿童，并预防新生儿感染艾滋病毒。目前，为了防止艾滋病毒从受感染的母亲传播给儿童，世界卫生组织建议从出生后3周开始服用抗逆转录病毒药物。唯一可用的儿童药物包括高浓度的酒精，以溶解水溶性差的药物。该计划中的纳米药物可分散在水中，并为儿科治疗提供了一个进步。支持新纳米医学的基础研究的成功建立将为英国在这一新兴领域的全球地位提供明显的进步，目前价值超过750亿美元，并迅速增长，预计在3年内达到1000亿美元。